Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments. - Muros-Le Rouzic E; Heer Y; Yiu S; Tozzi V; Braune S; van Hövell P; Bergmann A; Bernasconi C; Model F; Craveiro L (Journal of central nervous system disease, 2024)